CytoMed Therapeutics

CytoMed Therapeutics

Biotechnology
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.

$9.6M

Market Cap • 9/10/2026

2018

(8 years)

Founded

2023

(3 years ago)

IPO

NASDAQ

Listing Exchange

Flag of Singapore

Singapore

Country

Valuation

P/B

1,9

P/S

38

P/EBITDA

P/OCF

P/FCF

P/E

BVPS

0,4

EPS

Market Cap

Market Cap

9,6M

EV

8,6M

EV/Revenue

34

EV/EBITDA

-3

EV/EBIT

-2,7

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-2,3%

Total Yield

-2,3%

Payout

0%

Retained Earnings

-14,6M

Profitability

Gross Margin

79%

EBITDA Margin

EBIT Margin

Net Margin

D&A/EBITDA

0%

R&D/Revenue

683,6%

Capex/Revenue

196,6%

Capex/D&A

158,8%

Capex/OCF

-17,3%

SBC/OCF

% PPE

46,2%

% Goodwill

0%

ROE

ROIC

Growth

CAGR Op. Income 5Y

27,4%

CAGR Net Income 5Y

16,2%

CAGR EPS 5Y

0,8%

CAGR OCF 5Y

34,9%

Leverage

N.D./EBITDA

0,4

Debt/Equity

0%

Current Ratio

5,2

Quick Ratio

5,2

Interest Coverage

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium